Cargando…
Side effects during chemotherapy predict tumour response in advanced colorectal cancer
To investigate whether a relationship between chemotherapy-associated adverse events and treatment efficacy exists, we have analysed the toxicity, objective response and survival data of 303 patients with advanced colorectal cancer. Patients were divided into two groups: the first with beneficial ef...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361647/ https://www.ncbi.nlm.nih.gov/pubmed/16160693 http://dx.doi.org/10.1038/sj.bjc.6602783 |
_version_ | 1782153265154097152 |
---|---|
author | Schuell, B Gruenberger, T Kornek, G V Dworan, N Depisch, D Lang, F Schneeweiss, B Scheithauer, W |
author_facet | Schuell, B Gruenberger, T Kornek, G V Dworan, N Depisch, D Lang, F Schneeweiss, B Scheithauer, W |
author_sort | Schuell, B |
collection | PubMed |
description | To investigate whether a relationship between chemotherapy-associated adverse events and treatment efficacy exists, we have analysed the toxicity, objective response and survival data of 303 patients with advanced colorectal cancer. Patients were divided into two groups: the first with beneficial effect (I, n=245), and the second with progressive disease (II, n=58). Differences in terms of incidence rates, type and severity of adverse events were analysed with univariate and multivariate models. The median number of side effects in group I was 6 vs 4 in group II (OR=1.342; P=0.0001). An inverse correlation between disease control and treatment tolerance was confirmed when side effects were analysed according to severity and type of treatment-associated toxicities (haematological: P=0.0005 vs nonhaematological P=0.0001). When median survival was analysed according to the number of adverse events, it was 10 (95% CI, 3–7), 16 (14–18), and 18 (16–20) months in case of 0–1, 2–5, and ⩾6 adverse events, respectively (P=0.01). In conclusion, the results of this analysis suggest that occurrence of side effects during chemotherapy in advanced colorectal cancer is an independent and reliable prognostic indicator for response and survival. |
format | Text |
id | pubmed-2361647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23616472009-09-10 Side effects during chemotherapy predict tumour response in advanced colorectal cancer Schuell, B Gruenberger, T Kornek, G V Dworan, N Depisch, D Lang, F Schneeweiss, B Scheithauer, W Br J Cancer Clinical Study To investigate whether a relationship between chemotherapy-associated adverse events and treatment efficacy exists, we have analysed the toxicity, objective response and survival data of 303 patients with advanced colorectal cancer. Patients were divided into two groups: the first with beneficial effect (I, n=245), and the second with progressive disease (II, n=58). Differences in terms of incidence rates, type and severity of adverse events were analysed with univariate and multivariate models. The median number of side effects in group I was 6 vs 4 in group II (OR=1.342; P=0.0001). An inverse correlation between disease control and treatment tolerance was confirmed when side effects were analysed according to severity and type of treatment-associated toxicities (haematological: P=0.0005 vs nonhaematological P=0.0001). When median survival was analysed according to the number of adverse events, it was 10 (95% CI, 3–7), 16 (14–18), and 18 (16–20) months in case of 0–1, 2–5, and ⩾6 adverse events, respectively (P=0.01). In conclusion, the results of this analysis suggest that occurrence of side effects during chemotherapy in advanced colorectal cancer is an independent and reliable prognostic indicator for response and survival. Nature Publishing Group 2005-10-03 2005-09-13 /pmc/articles/PMC2361647/ /pubmed/16160693 http://dx.doi.org/10.1038/sj.bjc.6602783 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Schuell, B Gruenberger, T Kornek, G V Dworan, N Depisch, D Lang, F Schneeweiss, B Scheithauer, W Side effects during chemotherapy predict tumour response in advanced colorectal cancer |
title | Side effects during chemotherapy predict tumour response in advanced colorectal cancer |
title_full | Side effects during chemotherapy predict tumour response in advanced colorectal cancer |
title_fullStr | Side effects during chemotherapy predict tumour response in advanced colorectal cancer |
title_full_unstemmed | Side effects during chemotherapy predict tumour response in advanced colorectal cancer |
title_short | Side effects during chemotherapy predict tumour response in advanced colorectal cancer |
title_sort | side effects during chemotherapy predict tumour response in advanced colorectal cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361647/ https://www.ncbi.nlm.nih.gov/pubmed/16160693 http://dx.doi.org/10.1038/sj.bjc.6602783 |
work_keys_str_mv | AT schuellb sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer AT gruenbergert sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer AT kornekgv sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer AT dworann sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer AT depischd sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer AT langf sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer AT schneeweissb sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer AT scheithauerw sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer |